, the percentage value (%) for heterozygous group *6/*1 should be (24.5), instead of (24.6). 3. In the "Result" section, the following changes are made.
In
, the percentage value (%) for heterozygous group *6/*1 should be (24.5), instead of (24.6). 3. In the "Result" section, the following changes are made.
(a) The third sentence of subheading "CPT-11 administration" should be:
A total of 204 patients (51.3 %) in the wild-type group, 164 (50.2 %) in the heterozygous group, and 23 (32.9 %) in the homozygous group received a starting dose of CPT-11 of ≥142.5 mg/m 2 . (b) Under the subheading "Safety", the citations of Tables 4 and 5 should be interchanged. 4. In the "Discussion" section, the first sentence of the third paragraph should be:
The observed OR for the risk of neutropenia in the homozygous group compared with the wild-type group (2.22) was lower than (12.67-15.42) reported in previous studies [11, 17] .
Erratum to: Int J Clin Oncol DOI 10.1007/s10147-015-0937-x
Unfortunately, few errors appeared in the original article. They are corrected in this erratum.
1. In "Abstract", the first sentence of subsection "Results" should be:
A total of 795 patients were divided into wild-type (*1/*1) (50.1 %), heterozygous (*28/*1, *6/*1) (41.1 %), and homozygous (*28/*28, *6/*6, *28/*6) (8.8 %) groups, in which the median starting dose of CPT-11 was 143.0, 143.0, and 115.0 mg/m 2 , respectively.
